AGAINST BREAST CANCER LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Xeinadin Audit Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The accounts have been prepared on a going concern basis, as in the opinion of the Trustees, the charity will continue in operation for the foreseeable future.”

Group structure

1. AGAINST BREAST CANCER LIMITED · parent
   1. Against Breast Cancer Trading Limited 100% · England
   2. Against Breast Cancer Holdings Limited 100% · England

Significant events

• “2024 was a year of significant achievement for the charity, we were able to recognise and celebrate the success of our research team at our first research conference.”
• “Individually we congratulated research team members who were recipients of prestigious awards.”
• “Transfer of the DietCompLyf biobank to University of Southampton.”
• “The Biobank will make an important contribution to ongoing development of the miONCO test.”
• “The fundraising team resulted in a significant increase in the number of supporters taking part in events.”
• “The incredible Charity Angels team took their fundraising over £100,000.”
• “2024 was our busiest year on record for administering charitable estates. Gifts in Wills have contributed towards every discovery our research scientists have made.”
• “The multi-cancer early detection test, miONCO, moved into the commercialisation phase through the University spin-out company Xgenera.”
• “The miONCO early cancer detection test was reported in the national press (Oct 2024) with Health Secretary Wes Streeting calling it a 'game changing cancer test'.”
• “Max Crispin received new funding from the Bill & Melinda Gates Foundation of £1.4M over 2.5 years.”
• “Prof Max Crispin named to Clarivate's Highly Cited Researcher List 2024, recognised in the crossfield category.”
• “Successful application for funding from the Early-career researcher support fund, resulting in a donation of £142,511.”
• “A profit of £104,179 was made in 2024 compared to a loss of (£63,208) in 2023.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -2.8%

  £1,110,053 → £1,078,557

• Cash

  -32.2%

  £226,926 → £153,797

• Net assets

  +29.4%

  £353,989 → £458,168

• Employees

  -6.7%

  15 → 14

• Profit before tax

  +264.8%

  -£63,208 → £104,179

• Wages

  +9.3%

  £371,957 → £406,718

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers